A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19

Status:	Enrolling by invitation
Healthy:	No
Age Range:	Any
Updated:	9/14/2018
Start Date:	November 9, 2016
End Date:	March 2040

Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)

The purpose of this study is to evaluate the long-term safety and efficacy of UCART 19
administration to patients with advanced lymphoid malignancies.

Inclusion Criteria:

- Written informed consent obtained prior any study-specific procedure (patient or
parent(s) or legal representative)

- Patient dosed with UCART19 who completed or discontinued early from a sponsored or
from any investigator-initiated study that tested UCART19, or patients who were
administered UCART19 under a special access scheme (compassionate use);

- Female patients of childbearing potential and male patients with partners of
childbearing potential must continue to use an effective method of birth control as
well as their partners.

Exclusion Criteria:

- No exclusion criteria for this study

We found this trial at

sites

Childrens Hospital Los Angeles

4650 Sunset Blvd
Los Angeles, California 90027

(323) 660-2450